Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japan’s New Infertility Coverage To Drive The Market

ART Drugs Approved At Fast Pace

Executive Summary

Japan's national health insurance scheme will reimburse infertility treatments from April 2022, in a bid to make the treatments more accessible to patients by effectively lowering the cost by 70%. The key strategic aim is to raise a low birth rate and the move is also set to substantially expand the market for such products for both domestic and foreign players.

You may also be interested in...



Too Fast, Too Much? Japan Cuts Prices By 6.7% As Annual Revisions Bite

The Japanese government will apply new drug reimbursement prices from 1 April, under which Pfizer’s Vyndaqel will be slashed by 75% and UCB's E Keppra by 26%. Nobelpharma and Santen will be also affected by the revision, which averages close to 7% across the board.

Takeda Eyes Further Filings For Dengue Vaccine But Timings Unclear

With Qdenga’s US approval process moving ahead with the granting of a Priority Review and the dengue vaccine's first market launch, in Indonesia, expected early next year, Takeda has recently referred to plans to expand the product into other countries as well. But precise timings as yet remain unclear. 

Kyowa Kirin To Offload Selected Mature Portfolio To Grünenthal

The Japanese and German firms agree to establish a joint company to handle 13 mature brands from Kyowa Kirin's portfolio, mainly focused on pain management and including Abstral and PecFent. Grünenthal will own 51% and plans to fully buy out the operation in early 2026.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS145853

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel